Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
BELGRADE, Mont., Nov. 09, 2017 -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017.
The Company now plans to release its third quarter 2017 financial results in conjunction with the filing of its 10-Q which is currently expected to occur by November 20, 2017.
About Xtant Medical
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Investor Contact
CG CAPITAL
Rich Cockrell
877.889.1972
[email protected]
Company Contact
Xtant Medical
Molly Mason
[email protected]
